Increasing footprints in Vietnam in 2023, multinational corporations continue to eye stronger local partnerships to bring more new innovative medicines and vaccines to the local market in 2024 and beyond.
Japanâs health names latch onto Vietnam 14:00 | 05/02/2021
Vietnamâs healthcare expenditures reached around $17 billion in 2019, photo Le Toan
The second-largest pharmaceutical company in Japan, Daiichi Sankyo Co., Ltd., has entered a licence agreement with Mitsubishi Tanabe Pharma Corporation to register and launch edaravone brand Radicava in Vietnam. The medication treats patients with amyotrophic lateral sclerosis and helps with recovery from a stroke.
Yukinori Tominaga, general director of Daiichi Sankyo Vietnam Co., Ltd., told VIR, âWe are going to provide more access to new medications in order to increase options for Vietnamese doctors to improve the quality of life in Vietnamese people.â